BCL2 and acute myeloid leukemia: Fms-like tyrosine kinase 3 inhibitors targeting the most prevalent mutation in AML and Bcl-2 inhibitors directed against conserved oncogenic signaling pathways have emerged as the first-generation molecularly targeted agents in precision medicine for AML therapy [11,12].